A Study of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial Identifier: D8220C00027
Sponsor: AstraZeneca
Start Date: September 2022
Primary Completion Date: July 2027
Study Completion Date: April 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Geelong, AU, 3220
AU Nedlands, AU, 6009
AU Waratah, AU, 2298
CZ Hradec Kralove, CZ, 500 05
CZ Ostrava - Poruba, CZ, 708 52
CZ Pilsen, CZ, 30460, CZ
ES Barcelona, ES, 08025
ES Palma de Mallorca, ES, 07010
FR Montpellier, FR, 34295
FR TOURS, FR, 37044
HU Budapest, HU, 1097
HU Debrecen, HU, 4032
PL Bydgoszcz, PL, 85-168
PL Gdansk, PL, 80-219
PL Katowice, PL, 40-519
PL Kraków, PL, 30-727
PL Lódz, PL, 93-513
US, AZ Tucson, AZ, US, 85710
US, California La Jolla, California, US, 92093-0052
US, CO Longmont, CO, US, 80501
US, FL Jacksonville, FL, US, 32256
US, MA Boston, MA, US, 02115
US, MO Saint Louis, MO, US, 63110
US, NC Charlotte, NC, US, 28204
US, NY Buffalo, NY, US, 14263
US, NY New Hyde Park, NY, US, 11040
US, NY New York, NY, US, 10065
US, NY Rochester, NY, US, 14642
US, OH Cleveland, OH, US, 44195
US, OR Eugene, OR, US, 97401
US, PA Philadelphia, PA, US, 19104
US, TN Nashville, TN, US, 37203
US, UT Salt Lake City, UT, US, 84112
US, VA Charlottesville, VA, US, 22908
US, WA Seattle, WA, US, 98109
US, WA Seattle, WA, US, 98104